Status:
COMPLETED
Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China
Lead Sponsor:
Daiichi Sankyo
Collaborating Sponsors:
Daiichi Sankyo Co., Ltd.
Conditions:
Non-valvular Atrial Fibrillation
Eligibility:
All Genders
18+ years
Brief Summary
The safety of edoxaban treatment will be examined using real-world clinical evidence from adult patients with non-valvular atrial fibrillation (NVAF) indications in routine clinical practice.
Detailed Description
This non-interventional, observational study will evaluate the safety of edoxaban treatment in adult patients with NVAF indications with one or more risk factors. The primary objective of the study i...
Eligibility Criteria
Inclusion
- Written, informed consent
- NVAF-patients treated with edoxaban according to packaging information (i.e., for NVAF adult patients with one or more risk factors (such as history of congestive heart failure, hypertension, age ≥75 years old, diabetes, prior stroke or TIA) in prevention of stroke and systemic circulation embolism)
- Not participating in any interventional study at the same time
Exclusion
- Not applicable
Key Trial Info
Start Date :
February 26 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 27 2024
Estimated Enrollment :
5000 Patients enrolled
Trial Details
Trial ID
NCT04747496
Start Date
February 26 2021
End Date
November 27 2024
Last Update
January 9 2025
Active Locations (97)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Tsinghua Changgung Hospital Affiliated Hospital of Tsinghua University
Beijing, Changping District, China
2
Aviation General Hospital of China Medical University
Beijing, Chaoyang District, China
3
Beijing Anzhen Hospital, Capital Medical University
Beijing, Chaoyang District, China
4
Beijing Chao-Yang Hospital Capital Medical University
Beijing, Chaoyang District, China